Department of Microbiology and Immunology & National Research Laboratory of Dendritic Cell Differentiation & Regulation, Pusan National University School of Medicine, Yang-san 626-770, South Korea.
BMC Microbiol. 2010 Oct 15;10:263. doi: 10.1186/1471-2180-10-263.
Typhoid, which is caused by Salmonella enterica serovar Typhimurium, remains a major health concern worldwide. Multidrug-resistant strains of Salmonella have emerged which exhibit increased survivability and virulence, thus leading to increased morbidity. However, little is known about the protective immune response against this microorganism. The outer membrane protein (Omp)A of bacteria plays an important role in pathogenesis.
We purified OmpA from S. enterica serovar Typhimurium (OmpA-sal) and characterized the role of OmpA-sal in promoting adaptive and innate immune responses. OmpA-sal functionally activated bone marrow-derived dendritic cells by augmenting expression of CD80, CD86, and major histocompatibility complex classes I and II. Interestingly, OmpA-sal induced production of interferon-γ from T cells in mixed lymphocyte reactions, thus indicating Th1-polarizing capacity. The expression of surface markers and cytokine production in dendritic cells was mediated by the TLR4 signaling pathway in a TLR4 Knock-out system.
Our findings suggest that OmpA-sal modulates the adaptive immune responses to S. enterica serovar Typhimurium by activating dendritic cells and driving Th1 polarization, which are important properties to consider in the development of effective S. enterica serovar Typhimurium vaccines and immunotherapy adjuvant.
伤寒是由鼠伤寒沙门氏菌引起的,仍然是全球范围内的一个主要健康问题。沙门氏菌的多药耐药株已经出现,其表现出更高的生存能力和毒力,从而导致发病率增加。然而,人们对针对这种微生物的保护性免疫反应知之甚少。细菌的外膜蛋白(Omp)A 在发病机制中起着重要作用。
我们从鼠伤寒沙门氏菌(OmpA-sal)中纯化了 OmpA,并研究了 OmpA-sal 在促进适应性和先天免疫反应中的作用。OmpA-sal 通过增强 CD80、CD86 和主要组织相容性复合体 I 和 II 的表达,使骨髓来源的树突状细胞功能激活。有趣的是,OmpA-sal 在混合淋巴细胞反应中诱导 T 细胞产生干扰素-γ,从而表明其具有 Th1 极化能力。在 TLR4 敲除系统中,树突状细胞表面标志物的表达和细胞因子的产生是由 TLR4 信号通路介导的。
我们的研究结果表明,OmpA-sal 通过激活树突状细胞并驱动 Th1 极化来调节对鼠伤寒沙门氏菌的适应性免疫反应,这是在开发有效的鼠伤寒沙门氏菌疫苗和免疫治疗佐剂时需要考虑的重要特性。